# NASAL PHYTO

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nasal-phyto

- Industry: Pharmaceuticals
- Headquarters: Shenzhen, China
- Website: www.nasal-phyto.com
- Latest round: Series A (Sep 21, 2023)
- Investors on record: 2

## About

Based in Shenzhen, China and founded in 2019, NASAL PHYTO is a biotechnology and pharmaceutical company that focuses on development of innovative drugs for central nervous system diseases. The company has a R&D carrier platform and Innovation Center in Zhangjiang, and an Instrumentation Center in Shenzhen. It also cooperated with the Brain Drug Delivery Laboratory in Nanning. The company was awarded Shanghai Innovative Small and Medium-sized Enterprises of 2022. In September 2023, it raised series A funding.

NASAL PHYTO's main product category is a nasal drug delivery system for animals. Products within include Nasal-TDI, a series of innovative devices for precise olfactory spraying and dripping, NPRD003, a new and improved drug against cerebrovascular accidents, NPRD002, a new and improved antidepressant, NPRD004, a new and improved anticancer peptide, and NPRD001, a new and improved anti-Parkinson's Nasal Nano Class I drug. The RA-IDDS and Nasal-TDI drug delivery technology, which can be applied to preclinical basic research, and the solution of small dosage, unstable absorption, poor adaptability, poor parallelism and poor operability. The product can be used in the treatment of neurodegenerative diseases, psychoneurological diseases, strokes, brain tumors and other diseases.

The company's NPRD003 Anti-Cerebrovascular Accident Modified New Drug is expected to be declared for U.S. clinical studies by the end of 2023, and NPRD002 Anti-Depression Modified New Drug will be declared for U.S.-China clinical studies in early 2024.

## Funding rounds

- Series A, Sep 21, 2023 — Kaitai Capital, Yael Capital

## Investors

- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Series A
- Yael Capital (https://capitalatlas.ai/funds/yael-capital) — Series A